18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine patient care. This product is indicated for use in Positive Emission Tomography (PET) in adults and children.
It is used in the diagnosis of various neurological disorders (such as Parkinson's disease), but also in the imaging of specific neuroendocrine tumors.

Neurology

PET with fluorodopa (18F) is indicated to demonstrate a loss of functional dopaminergic nerve endings in the striatum. Defects in dopamine housings are associated with various neurological disorders such as Parkinson's disease. It is therefore used to distinguish essential tremor from parkinsonistic syndromes related to degenerative disorders of the nigrostriatal system (Parkinson's disease, multiple system atrophy and progressive supranuclear palsy).

Oncology

Studies on imaging research show that PET with fluorodopa (18F) allows for a functional approach of pathologies, organs or tissues looking for an increase in intracellular transport and decarboxylation of the amino acid dihydroxyphenylalanine.

Interested in 18F-FDOPA? Contact us to discuss the possibilities.


18F-FDOPA now available

Other news

1st production QuiremSpheres

1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...

Read more

Production of novel diagnostic radionuclides in small medical cyclotrons

Production of novel diagnostic radionuclides in small medical cyclotrons

Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...

Read more

First liver cancer patient treated with microspheres irradiated in TU Delft

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

Read more

Upcoming event

Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.